Medscape4d
The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Beta-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose
NH2-terminal GIP immunoreactivity was measured using the specific antiserum 98171, which cross-reacts <0.1% with GIP3-42 or with structurally related GLP peptides or glucagon. Addition of ...
The Lancet1d
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...
pharmaphorum4d
Novo Nordisk asks FDA not to allow GLP-1 compounding
Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...
pharmaphorum6d
Novo joins Lilly in asking FDA for ban on GLP-1 compounding
Earlier this month, the FDA put out a statement saying that it, too, was concerned about patients and healthcare professionals turning to unapproved versions of GLP-1 drugs as an option for weight ...
Frontiers3d
Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular Carcinoma
Tumor-targeting peptides functioned as molecular probes are essential for multi-modality imaging and molecular-targeting therapy in caner theronostics. Here, we performed a phage-displayed bio-panning ...
Frontiers3d
Function of gastrin-releasing peptide receptors in ocular itch transmission in the mouse trigeminal sensory system
We focused on the gastrin-releasing peptide (GRP) and GRP receptor (GRPR), which are reportedly involved in itch transmission in the spinal somatosensory system, to determine whether the GRP system is ...